Etanercept e infliximab

LAVORI DI REVISIONE AAVV. Il pediatra e la malattia infiammatoria cronica intestinale. Medico e Bambino 1998; 8:19-43. Van Hogezand RA, Verspaget HW. The future role of anti-tumour necrosis factor-alfa products in the treatment of Crohn’s disease. Drugs 1998;56(3):299-305. Infliximab per il morbo di Crohn. The Medical Letter (ed italiana) 1999;8:33-4. Martini A. Nuove prospettive nel trattamento delle malattie reumatiche. Prospettive in Pediatria 1999;29:25-31. Nuovi farmaci per l’artrite reumatoide. The Medical Letter (ed italiana) 1999;2:6-8. Venegoni M. Etanercept e infliximab. Occhio Clinico 1999;6:30. Jarvis B, Faulds D. Etanercept. A review of its use in rheumatoid arthritis. Drugs 1999;57 (6):945-66. O’Dell JR. Anticytokine therapy. A new era in the treatment of rheumatoid arthritis? N Engl J Med 1999;340:310-2. STUDI CLINICI ARTRITE REUMATOIDE Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7. Moreland LW, Schiff MH, Baumgartener SW, at al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled study. Ann Intern Med 1999;130:478-86. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of Etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9. Lovell DJ, Giannini EH, Whitmore JB, et al. Safety and efficacy of tumor necrosis factor receptor p75 FC fusion protein (TNFR:FC, Enbrel) in polyarticular course juvenile rheumatoid arthritis (abstract no. 584). Arthritis Rheum 1998;41:Suppl:S130. Elliot MJ, Maini RN, Feldmann M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alfa (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alfa monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63. Maini R, William St Clair E, Breedveld F, et al. For the Attract Study Group, Infliximab (chimeric anti-tumor necrosis factor alfa monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate; a randomized phase III trial. Lancet 1999;354:1932-9. MALATTIA DI CROHN Targan SR, Hanauer S, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alfa for Crohn’s disease. N Engl J Med 1997;337: 1029-35. Present DH, Rutgeerts P, Targan S, et al. Infliximab for treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340:1398-405.